MTOR: The Rapid Aging  Pathway 

“The mammalian target of rapamycin(mTOR), also known as the mechanistic target of rapamycin and FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene.^[5][6][7] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases.^[8]

mTOR links with other proteins and serves as a core component of two distinct protein complexes, mTOR complex 1 and mTOR complex 2, which regulate different cellular processes.^[9] In particular, as a core component of both complexes, mTOR functions as a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription.^[9][10] As a core component of mTORC2, mTOR also functions as a tyrosine protein kinase that promotes the activation of insulin receptors and insulin-like growth factor 1 receptors.^[11]mTORC2 has also been implicated in the control and maintenance of the actin cytoskeleton.^[9][12]

mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids.^[10] mTOR also senses cellular nutrient, oxygen, and energy levels.^[27] The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue,^[28] and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers.^[29][30]

Decreased TOR activity has been found to increase life span in S. cerevisiae, C. elegans, and D. melanogaster.^{[61][62][63][64]} The mTOR inhibitor rapamycin has been confirmed to increase lifespan in mice.^{[65][66][67][68][69]}

It is hypothesized that some dietary regimes, like caloric restriction and methionine restriction, cause lifespan extension by decreasing mTOR activity.^[61][62] Some studies have suggested that mTOR signaling may increase during aging, at least in specific tissues like adipose tissue, and rapamycin may act in part by blocking this increase.^[70] An alternative theory is mTOR signaling is an example of antagonistic pleiotropy, and while high mTOR signaling is good during early life, it is maintained at an inappropriately high level in old age. Calorie restriction and methionine restriction may act in part by limiting levels of essential amino acids including leucine and methionine, which are potent activators of mTOR.^[71] The administration of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway in the hypothalamus.^[72]

According to the free radical theory of aging,^[73] reactive oxygen species cause damage of mitochondrial proteins and decrease ATP production. Subsequently, via ATP sensitive AMPK, the mTOR pathway is inhibited and ATP consuming protein synthesis is downregulated, since mTORC1 initiates a phosphorylation cascade activating the ribosome.^[16] Hence, the proportion of damaged proteins is enhanced. Moreover, disruption of mTORC1 directly inhibits mitochondrial respiration.^[74]These positive feedbacks on the aging process are counteracted by protective mechanisms: Decreased mTOR activity (among other factors) upregulates glycolysis^[74] and removal of dysfunctional cellular components via autophagy.^{[73]“ — Wikipedia} 

Simplified in plain English:

KEEP MTOR TURNED OFF as often as possible.

MTOR = RAPID AGING.

You want ZERO amino acids (ie. protein),  glucose or MCT fats during fasting window as these all require insulin and ACTIVATE MTOR. You want ZERO CALORIES. ZERO INSULIN SECRETION.

Whats left?

Interstellar Blends, matcha green tea, and black coffee are ok and all inhibit mTOR; utilize these during your fasting window to remain energized, mentally clear, emotionally elevated and feeling all around amazing while staying young by keeping mTOR turned OFF.

1000 SCIENTIFIC STUDIES

1. mTOR in Aging , metabolism, and cancer
2. mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
3. Rapalogs and mTOR inhibit ors as anti-Aging therapeutics
4. mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging
5. Roles of the Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and Aging
6. calorie restriction : Decelerating mTOR -driven Aging from cells to organisms (including humans)
7. BMAL1-dependent regulation of the mTOR signaling pathway delays Aging
8. Increased Mammalian Lifespan and a Segmental and Tissue-Specific Slowing of Aging after Genetic Reduction of mTOR Expression
9. PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in Aging , cognitive decline and Alzheimer’s disease
10. Molecular damage in cancer : an argument for mTOR -driven Aging
11. mTOR signaling in Aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy
12. Caveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment: Chemoprevention with Rapamycin, an mTOR inhibit or and Anti-Aging Drug
13. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer , obesity, and Aging
14. Potential anti-Aging agents suppress the level of constitutive mTOR – and DNA damage- signaling
15. mTOR signalling: the molecular interface connecting metabolic stress, Aging and cardiovascular diseases
16. mTOR Signaling from Cellular Senescence to Organismal Aging
17. Modulating mTOR in Aging and Health
18. Ral and Rheb GTPase Activating Proteins Integrate mTOR and GTPase Signaling in Aging , Autophagy, and Tumor Cell Invasion
19. mTOR and autophagy in normal brain Aging and caloric restriction ameliorating age-related cognition deficits
20. From growing to secreting: New roles for mTOR in Aging cells
21. mTOR inhibit ion: From Aging to Autism and Beyond
22. Mechanistic or mammalian target of rapamycin (mTOR ) may determine robustness in young male mice at the cost of accelerated Aging
23. Effects of Aging and gender on muscle mass and regulation of Akt-mTOR -p70s6k related signaling in the F344BN rat model
24. M(o)TOR of Aging : mTOR as a universal molecular hypothalamus
25. mTOR -driven quasi-programmed Aging as a disposable soma theory: Blind watchmaker vs. intelligent designer
26. longevity Pathways (mTOR , SIRT, insulin /IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
27. Aging and cancer : can mTOR inhibit ors kill two birds with one drug?
28. mTOR and its link to the picture of Dorian Gray – re-activation of mTOR promotes Aging
29. Aberrant mTOR activation in senescence and Aging : A mitochondrial stress response?
30. The proliferation of amplifying neural progenitor cells is impaired in the Aging brain and restored by the mTOR pathway activation
31. Kinase mTOR : Regulation and role in maintenance of cellular homeostasis, tumor development, and Aging
32. HMGA2 regulates the in vitro Aging and proliferation of human umbilical cord blood-derived stromal cells through the mTOR /p70S6K signaling pathway
33. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow Aging . Coincidences with calorie restriction and mTOR inhibit ion
34. Coenzyme Q10 inhibit s the Aging of Mesenchymal Stem Cells Induced by D-Galactose through Akt/mTOR Signaling
35. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven Aging
36. Ampelopsin attenuates brain Aging of D-gal-induced rats through miR-34a-mediated SIRT1/mTOR signal pathway
37. Vascular mTOR -dependent mechanisms linking the control of Aging to Alzheimer’s disease
38. mTOR as Regulator of Lifespan, Aging , and Cellular Senescence: A Mini-Review
39. restriction on an Energy-Dense Diet Improves Markers of Metabolic Health and Cellular Aging in Mice Through Decreasing Hepatic mTOR Activity
40. mTOR : at the crossroads of Aging , chaperones, and Alzheimer’s disease
41. Adaptation to chronic mTOR inhibit ion in cancer and in Aging
42. The Phosphatidylinositol 3-Kinase/mTOR Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration
43. Alleviation of senescence and epithelial-mesenchymal transition in Aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK /mTOR signaling
44. Erythropoietin and mTOR : A “One-Two Punch” for Aging -Related Disorders Accompanied by Enhanced Life Expectancy
45. mTOR Signaling Fades POMC Neurons during Aging
46. mTOR signaling plays a critical role in the defects observed in muscle‐derived stem/progenitor cells isolated from a murine model of accelerated Aging
47. The role of mTOR signaling in Alzheimer disease
48. Conservative Growth Hormone/IGF-1 and mTOR Signaling Pathways as a Target for Aging and cancer Prevention: Do We Really Have an AntiAging Drug
49. Gene expression analysis of mTOR pathway: association with human longevity
50. Rapamycin-Induced insulin Resistance Is Mediated by mTOR C2 Loss and Uncoupled from longevity
51. Diminished mTOR signaling: a common mode of action for endocrine longevity factors
52. The Role of mTOR Signaling in Controlling Mammalian Life Span: What a Fungicide Teaches Us About longevity
53. longevity Pathways (mTOR , SIRT, insulin /IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
54. PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in Aging , cognitive decline and Alzheimer’s disease
55. The role of mitochondria in mTOR ‐regulated longevity
56. Augmented autophagy pathways and mTOR modulation in fibroblasts from long-lived mutant mice
57. hNAG-1 increases lifespan by regulating energy metabolism and insulin /IGF-1/mTOR signaling
58. Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression
59. SIRT1 activator (SRT1720) improves the follicle reserve and prolongs the ovarian lifespan of diet-induced obesity in female mice via activating SIRT1 and suppressing mTOR signaling
60. Chronic inhibit ion of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
61. Differential control of ageing and lifespan by isoforms and splice variants across the mTOR network
62. mTOR , cancer and Transplantation
63. Defining the Role of mTOR in cancer
64. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
65. mTOR and cancer : insights into a complex relationship
66. mTOR , translation initiation and cancer
67. mTOR and cancer therapy
68. The Akt-mTOR tango and its relevance to cancer
69. mTOR -targeted therapy of cancer with rapamycin derivatives
70. An expanding role for mTOR in cancer
71. The mTOR Signalling Pathway in Human cancer
72. Targeting mTOR signaling for cancer therapy
73. Targeting the mTOR Signaling Network for cancer Therapy
74. The translational landscape of mTOR signalling steers cancer initiation and metastasis
75. Hypoxia signalling through mTOR and the unfolded protein response in cancer
76. Targeting Pi3k /Akt/mTOR signaling in cancer
77. Hypoxia-inducible factor determines sensitivity to inhibit ors of mTOR in kidney cancer
78. mTOR and cancer : many loops in one pathway
79. mTOR , a novel target in breast cancer : the effect of CCI-779, an mTOR inhibit or, in preclinical models of breast cancer .
80. mTOR in Aging , metabolism, and cancer
81. mTOR inhibit ors in cancer therapy
82. Targeting the mTOR signaling network in cancer
83. PI3K/Akt/mTOR pathway as a target for cancer therapy. therapy
84. mTOR signaling and drug development in cancer
85. Akt-dependent and -independent mechanisms of mTOR regulation in cancer
86. mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer
87. Targeting mTOR : prospects for mTOR complex 2 inhibit ors in cancer therapy
88. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
89. Molecular targets for cancer therapy in the Pi3k /AKT/mTOR pathway
90. Targeting the mammalian target of rapamycin (mTOR ): a new approach to treating cancer
91. mTOR signaling: implications for cancer and anticancer therapy
92. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer
93. Will mTOR inhibitors make it as cancer drugs?
94. Activation of the PTEN/mTOR /STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
95. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
96. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR inhibit or, in Patients With cancer
97. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
98. Targeting AKT/mTOR and ERK MAPK signaling inhibit s hormone-refractory prostate cancer in a preclinical mouse model
99. mTOR Complex 2 Is Required for the Development of Prostate cancer Induced by Pten Loss in Mice
100. Targeting tumorigenesis: development and use of mTOR inhibit ors in cancer therapy
101. Targeting the Pi3k /AKT/mTOR pathway in estrogen receptor-positive breast cancer
102. Oral mTOR inhibit or Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic cancer
103. mTOR mediated anti-cancer drug discovery
104. Targeting PI3 Kinase/AKT/mTOR Signaling in cancer
105. Phase II Study of Temsirolimus (CCI-779), a Novel inhibit or of mTOR , in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast cancer
106. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
107. inhibit ion of Pi3k /mTOR Leads to Adaptive Resistance in Matrix-Attached cancer Cells
108. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
109. PI 3-kinase, mTOR , protein synthesis and cancer
110. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
111. Current treatment strategies for inhibit ing mTOR in cancer
112. Targeted Therapy for Advanced Prostate cancer : inhibit ion of the Pi3k /Akt/mTOR Pathway
113. Not all substrates are treated equally: Implications for mTOR , rapamycin-resistance, and cancer therapy
114. mTOR inhibit ors in the treatment of cancer
115. Role of Pi3k /AKT/mTOR signaling in the cell cycle progression of human prostate cancer
116. The Molecular Target of Rapamycin (mTOR ) as a Therapeutic Target Against cancer
117. Targeting the Pi3k /Akt/mTOR pathway in castration-resistant prostate cancer
118. Expression of mTOR signaling pathway markers in prostate cancer progression
119. mTOR Pathway and mTOR inhibit ors as Agents for cancer Therapy
120. The Pi3k /AKT/mTOR pathway in breast cancer : targets, trials and biomarkers
121. A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian cancer
122. Targeting mTOR globally in cancer : Thinking beyond rapamycin
123. Aspirin inhibit s mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal cancer Cells
124. The mTOR Pathway: A New Target in cancer Therapy
125. Phosphatidic acid signaling to mTOR : Signals for the survival of human cancer cells
126. Adiponectin inhibit s colorectal cancer cell growth through the AMPK /mTOR pathway
127. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
128. G1 cell cycle progression and the expression of G1 cyclins are regulated by Pi3k /AKT/mTOR /p70S6K1 signaling in human ovarian cancer cells
129. Targeting Pi3k /AKT/mTOR pathway in non small cell lung cancer
130. Specific apoptosis induction by the dual Pi3k /mTOR inhibit or NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
131. Pi3k and mTOR Signaling Pathways in cancer : New Data on Targeted Therapies
132. Targeting the Pi3k /AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
133. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
134. Effects of the mTOR inhibit or sirolimus in patients with hepatocellular and cholangiocellular cancer
135. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.
     
136. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
137. Mechanisms of mTOR inhibit or resistance in cancer therapy
138. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
139. Pi3k /Akt/mTOR inhibit ors in breast cancer
140. mTOR signaling for biological control and cancer
141. The Pi3k /AKT/mTOR pathway as a therapeutic target in ovarian cancer
142. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the Pi3k /Akt/mTOR pathway in prostate cancer radioresistance
143. Novel Expression Patterns of Pi3k /Akt/mTOR Signaling Pathway Components in Colorectal cancer
144. Targeting mTOR for cancer Treatment
145. mTOR Signaling Pathway Is a Target for the Treatment of Colorectal cancer
146. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
147. mTOR Signaling Pathway and mTOR inhibit ors in cancer Therapy
148. Alternative phospholipase D/mTOR survival signal in human breast cancer cells
149. Quercetin induces protective autophagy in gastric cancer cells: Involvement of Akt-mTOR – and hypoxia-induced factor 1α-mediated signaling
150. inhibit ors of the Pi3k /Akt/mTOR Pathway: New Hope for Breast cancer Patients
151. A phase 2 study with a daily regimen of the oral mTOR inhibit or RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
152. mTOR inhibit ors in cancer therapy
153. GDC-0980 Is a Novel Class I Pi3k /mTOR Kinase inhibit or with Robust Activity in cancer Models Driven by the Pi3k Pathway
154. mTOR kinase inhibit ors as potential cancer therapeutic drugs
155. Expanding therapeutic targets in bladder cancer : the Pi3k /Akt/mTOR pathway
156. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
157. Genetic Variations in the Pi3k /PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal cancer Patients Treated With Chemoradiotherapy
158. AKT and cancer —Is it all mTOR ?
159. Targeting the Pi3k -AKT-mTOR signaling network in cancer
160. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells
161. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
162. The Potential Role of mTOR inhibit ors in Non-Small Cell Lung cancer
163. Potential Targets for Prevention of Colorectal cancer : a Focus on Pi3k /Akt/mTOR and Wnt Pathways
164. Oxygen-independent Regulation of HIF-1: Novel Involvement of Pi3k / AKT/mTOR Pathway in cancer
165. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
166. mTOR pathway in colorectal cancer : an update
167. mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.
168. JAK2/STAT5 inhibit ion Circumvents Resistance to Pi3k /mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast cancer
169. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibit ory drugs
170. Targeting mTOR signaling in lung cancer
171. Pi3k /Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application
172. mTOR signaling in human cancer
173. Compound C induces protective autophagy in cancer cells through AMPK inhibit ion-independent blockade of Akt/mTOR pathway
174. Pi3k -AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
175. mTOR and cancer : reason for dancing at the crossroads?
176. Enhancing mTOR -targeted cancer therapy
177. Targeting mTOR pathway: A new concept in cancer therapy
178. Hypoxia inhibit s Protein Synthesis through a 4E-BP1 and Elongation Factor 2 Kinase Pathway Controlled by mTOR and Uncoupled in Breast cancer Cells
179. Autophagy upregulation by inhibit ors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
180. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibit ors
181. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.
182. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer
183. Deciphering the Role of Pi3k /Akt/mTOR Pathway in Breast cancer Biology and Pathogenesis
184. Targeting mTOR dependency in pancreatic cancer
185. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells
186. mTOR as a Target for cancer Therapy
187. PLC and Pi3k /Akt/mTOR signalling in disease and cancer
188. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway
189. Down‐regulation of Notch‐1 and Jagged‐1 inhibit s prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR , and NF‐κB signaling pathways
190. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells
191. In vivo antitumor effect of the mTOR inhibit or CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer
192. Antidiabetic Drug Metformin Prevents Progression of Pancreatic cancer by Targeting in Part cancer Stem Cells and mTOR Signaling
193. The oral mTOR inhibit or RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer : Results of a phase I study with pharmacokinetics
194. mTOR inhibit ors for hepatocellular cancer : a forward-moving target
195. Rapamycin and mTOR : a serendipitous discovery and implications for breast cancer
196. Mammalian Target of Rapamycin (mTOR ) inhibit ors as Anti-cancer Agents
197. Metformin promotes progesterone receptor expression via inhibit ion of mammalian target of rapamycin (mTOR ) in endometrial cancer cells
198. Relation between outcomes and localisation of p-mTOR expression in gastric cancer
199. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
200. Development of Pi3k /AKT/mTOR Pathway inhibit ors and Their Application in Personalized Therapy for Non–Small-Cell Lung cancer
201. A phase II trial of the mTOR inhibit or AP23573 as a single agent in advanced endometrial cancer
202. Rottlerin induces autophagy which leads to apoptotic cell death through inhibit ion of Pi3k /Akt/mTOR pathway in human pancreatic cancer stem cells
203. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR /S6K2 signaling pathway
204. Pi3k /Akt/mTOR Pathway inhibit ors in cancer : A Perspective on Clinical Progress
205. The Pharmacology of mTOR inhibit ion
206. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
207. The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast cancer
208. Simvastatin inhibit s Renal cancer Cell Growth and Metastasis via AKT/mTOR , ERK and JAK2/STAT3 Pathway
209. The Pi3k /AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance
210. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via Pi3k /Akt/mTOR signaling pathway
211. Recent Clinical Trials of mTOR -Targeted cancer Therapies
212. Docosahexaenoic acid induces autophagy through p53/AMPK /mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53
213. Dietary flavonoid fisetin: A novel dual inhibit or of Pi3k /Akt and mTOR for prostate cancer management
214. Thioridazine induces apoptosis by targeting the Pi3k /Akt/mTOR pathway in cervical and endometrial cancer cells
215. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
216. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2‐overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation
217. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
218. The VEGF pathway and the AKT/mTOR /p70S6K1 signalling pathway in human epithelial ovarian cancer
219. Phase I trial of oral mTOR inhibit or everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
220. Effects of a combined treatment with mTOR inhibit or RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
221. The Importance of the Pi3k /AKT/mTOR Pathway in the Progression of Ovarian cancer
222. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells
223. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer
224. Molecular damage in cancer : an argument for mTOR -driven Aging
225. mTOR in renal cell cancer : modulator of tumor biology and therapeutic target
226. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer , obesity, and Aging
227. Allosteric and ATP-competitive kinase inhibit ors of mTOR for cancer treatment
228. A review of oral toxicity associated with mTOR inhibit or therapy in cancer patients
229. LKB1/AMPK /mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology
230. Current clinical regulation of Pi3k /PTEN/Akt/mTOR signalling in treatment of human cancer
231. Deciphering downstream gene targets of Pi3k /mTOR /p70S6K pathway in breast cancer
232. Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in cancer Cells
233. Pi3k /AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
234. Temsirolimus, an mTOR inhibit or, enhances anti-tumour effects of heat shock protein cancer vaccines
235. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibit ion of cell proliferation and modulation of the mTOR pathway
236. Silibinin inhibit s hypoxia-inducible factor-1α and mTOR /p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy
237. mTOR Signaling in cancer Cell Motility and Tumor Metastasis
238. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables
239. Pi3k /Akt/mTOR pathway inhibit ors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
240. The expanding role of mTOR in cancer cell growth and proliferation
241. mTOR as a therapeutic target in patients with gastric cancer
242. mTOR -independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibit ors
243. mTOR inhibit or Treatment of Pancreatic cancer in a Patient With Peutz-Jeghers Syndrome
244. Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (Pi3k )/Mammalian Target of Rapamycin (mTOR ) Kinase inhibit or (GDC-0980) for the Treatment of cancer
245. The Dual Pi3k /mTOR inhibit or NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal cancer
246. TGF-β Effects on Prostate cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of Pi3k /AKT/mTOR Pathway
247. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.
248. Fucoidan from Seaweed Fucus vesiculosus inhibit s Migration and Invasion of Human Lung cancer Cell via Pi3k -Akt-mTOR Pathways
249. Integrated preclinical and clinical development of mTOR inhibit ors in pancreatic cancer
250. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
251. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the Pi3k /Akt/mTOR signaling pathway
252. Genetic variations in Pi3k -AKT-mTOR pathway and bladder cancer risk
253. Targeting Pi3k /Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
254. Simultaneous inhibit ion of mTOR C1 and mTOR C2 by mTOR kinase inhibit or AZD8055 induces autophagy and cell death in cancer cells
255. Targeting mTOR network in colorectal cancer therapy
256. Targeting the Pi3k /Akt/mTOR Axis by Apigenin for cancer Prevention
257. Pi3k /Akt/mTOR signaling in medullary thyroid cancer : a promising molecular target for cancer therapy
258. Genomic Loss of Tumor Suppressor miRNA-204 Promotes cancer Cell Migration and Invasion by Activating AKT/mTOR /Rac1 Signaling and Actin Reorganization
259. Therapeutic targeting of the mTOR ‐signalling pathway in cancer : benefits and limitations
260. From Rapa Nui to rapamycin: targeting Pi3k /Akt/mTOR for cancer therapy
261. Pi3k /AKT/mTOR inhibit ors In Ovarian cancer
262. Metformin and the mTOR inhibit or Everolimus (RAD001) Sensitize Breast cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro
263. Resveratrol enhances the anti-tumor activity of the mTOR inhibit or rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling
264. A liaison between mTOR signaling, ribosome biogenesis and cancer
265. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
266. Dual inhibit ion of EGFR and mTOR pathways in small cell lung cancer
267. Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets
268. Repurposing of Metformin and Aspirin by Targeting AMPK-mTOR and Inflammation for Pancreatic Cancer Prevention and Treatment
269. Licorice and Licochalcone-A Induce Autophagy in LNCaP Prostate cancer Cells by Suppression of Bcl-2 Expression and the mTOR Pathway
270. LKB1/AMPK /mTOR Signaling Pathway in Non-small-cell Lung cancer
271. Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR inhibit ors and Metformin in Pancreatic cancer Cells
272. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
273. Prognostic role of p‐mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer
274. E2F1 inhibit s c-Myc-Driven Apoptosis via PIK3CA/Akt/mTOR and COX-2 in a Mouse Model of Human Liver cancer
275. mTOR Signaling in Protein Translation Regulation: Implications in cancer Genesis and Therapeutic Interventions
276. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer
277. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR , PTEN , STK11 , RPKAA1 , PRKAG2 , TSC1 , TSC2 , Pi3k and Akt1
278. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
279. Curcumin inhibit s the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
280. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
281. Targeting the Pi3k /Akt/mTOR Pathway for Breast cancer Therapy
282. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway
283. Overcoming acquired resistance to letrozole by targeting the Pi3k /AKT/mTOR pathway in breast cancer cell clones
284. Dissecting the role of mTOR : Lessons from mTOR inhibit ors
285. 6-Shogaol, an Active Constituent of Dietary Ginger, Induces Autophagy by inhibit ing the AKT/mTOR Pathway in Human Non-Small Cell Lung cancer A549 Cells
286. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.
287. Glucose metabolism and cancer
288. Rhodiola rosea extract s and salidroside decrease the growth of bladder cancer cell lines via inhibit ion of the mTOR pathway and induction of autophagy
289. Targeted Regulation of Pi3k /Akt/mTOR /NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for cancer Therapy
290. Current Status and Challenges Associated with Targeting mTOR for cancer Therapy
291. Pi3k -AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate cancer Cells
292. The mTOR Pathway in Breast cancer
293. mTOR inhibit ion reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels
294. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
295. HIF1α Regulates mTOR Signaling and Viability of Prostate cancer Stem Cells
296. Involvement of Akt-1 and mTOR in Sensitivity of Breast cancer to Targeted Therapy
297. inhibit ion of mTOR Signaling by Quercetin in cancer Treatment and Prevention
298. Plumbagin induces apoptotic and autophagic cell death through inhibit ion of the Pi3k /Akt/mTOR pathway in human non-small cell lung cancer cells
299. Overexpression of the μ-Opioid Receptor in Human Non-Small Cell Lung cancer Promotes Akt and mTOR Activation, Tumor Growth, and Metastasis
300. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
301. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.
302. Attenuated mTOR Signaling and Enhanced Autophagy in Adipocytes from Obese Patients with Type 2 diabetes
303. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
304. The Tuberin/mTOR Pathway Promotes Apoptosis of Tubular Epithelial Cells in diabetes
305. mTOR inhibit ors and diabetes
306. The role of mTOR in the adaptation and failure of β‐cells in type 2 diabetes
307. mTOR : Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus
308. The role of mammalian target of rapamycin (mTOR ) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes
309. Insights for oxidative stress and mTOR Signaling in Myocardial Ischemia/Reperfusion Injury under diabetes
310. Phospho-mTOR : A novel target in regulation of renal lipid metabolism abnormality of diabetes
311. mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer’s disease
312. Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes
313. Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR
314. Leucine Stimulates insulin Secretion via Down-regulation of Surface Expression of Adrenergic α2A Receptor through the mTOR (Mammalian Target of Rapamycin) Pathway
     IMPLICATION IN NEW-ONSET diabetes IN RENAL TRANSPLANTATION
315. The role of mTOR in lipid homeostasis and diabetes progression
316. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes
317. The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 diabetes Mellitus
318. Investigation of Pi3k /PKB/mTOR /S6K1 signaling pathway in relationship of type 2 diabetes and Alzheimer’s disease
319. Association of Pi3k /AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese
320. diabetes Diminishes Phosphatidic Acid in the Retina: A Putative Mediator for Reduced mTOR Signaling and Increased Neuronal Cell Death
321. mTOR and Cardiovascular Diseases: Diabetes Mellitus.
322. Analysis of single nucleotide polymorphisms implicate mTOR signalling in the development of new-onset diabetes after transplantation
323. microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus
324. 1,25(OH)2D3 improves cardiac dysfunction, hypertrophy, and fibrosis through PARP1/SIRT1/mTOR ‐related mechanisms in type 1 diabetes
325. High glucose induces formation of tau hyperphosphorylation via Cav-1-mTOR pathway: A potential molecular mechanism for diabetes -induced cognitive dysfunction
326. Supplementation with polyunsaturated fatty acids in pregnant rats with mild diabetes normalizes placental PPARγ and mTOR signaling in female offspring developing gestational diabetes
327. Associations between INSR and mTOR polymorphisms in type 2 diabetes mellitus and diabetic nephropathy in a Northeast Chinese Han population
328. Anabolic resistance does not explain sarcopenia in patients with type 2 diabetes mellitus, compared with healthy controls, despite reduced mTOR pathway activity
329. Tuberin and mTOR , a key apoptotic pathway indiabetes
330. inhibit ion of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan
331. Amino Acid and insulin Signaling via the mTOR /p70 S6 Kinase Pathway
     A NEGATIVE FEEDBACK MECHANISM LEADING TO insulin RESISTANCE IN SKELETAL MUSCLE CELLS
332. Down-regulation of placental mTOR , insulin /IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon
333. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibit ion of insulin signaling through insulin receptor substrate-1
334. Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR -Mediated insulin Receptor Substrate 1 Phosphorylation
335. insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase
336. Stimulation of the insulin /mTOR pathway delays cone death in a mouse model of retinitis pigmentosa
337. mTOR ‐dependent stimulation of the association of eIF4G and eIF3 by insulin
338. MAP kinases and mTOR mediate insulin -induced phosphorylation of insulin Receptor Substrate-1 on serine residues 307, 612 and 632
339. Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways.
340. Amino Acids and insulin Control Autophagic Proteolysis through Different Signaling Pathways in Relation to mTOR in Isolated Rat Hepatocytes
341. Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and insulin on Initiation Factor 4E-Binding Proteins
342. Regulation of insulin signalling by hyperinsulin aemia: role of IRS-1/2 serine phosphorylation and the mTOR /p70 S6K pathway
343. Mammalian target of rapamycin (mTOR ) inhibit ion activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin -like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibit ion of both pathways
344. Long‐chain omega‐3 fatty acids regulate bovine whole‐body protein metabolism by promoting muscle insulin signalling to the Akt–mTOR –S6K1 pathway and insulin sensitivity
345. Activation of Mammalian Target of Rapamycin (mTOR ) by insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1
346. insulin – and Leptin-Mediated Control of Aquaglyceroporins in Human Adipocytes and Hepatocytes Is Mediated via the Pi3k /Akt/mTOR Signaling Cascade
347. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors.
348. Chronic mTOR inhibit ion by rapamycin induces muscle insulin resistance despite weight loss in rats
349. Insulin Stimulates Mitochondrial Fusion and Function in Cardiomyocytes via the Akt-mTOR-NFkB-Opa-1 Signaling Pathway
350. Glycerolipid signals alter mTOR complex 2 (mTOR C2) to diminish insulin signaling
351. insulin promotes dendritic spine and synapse formation by the Pi3k /Akt/mTOR and Rac1 signaling pathways
352. The TSC-mTOR Pathway Mediates Translational Activation of TOP mRNAs by insulin Largely in a Raptor- or Rictor-Independent Manner
353. insulin Receptor Substrate-2 Proteasomal Degradation Mediated by a Mammalian Target of Rapamycin (mTOR )-induced Negative Feedback Down-regulates Protein Kinase B-mediated Signaling Pathway in β-Cells
354. IKKβ suppression of TSC1 function links the mTOR pathway with insulin resistance
355. The Cardioprotection of the insulin -Mediated Pi3k /Akt/mTOR Signaling Pathway
356. Mammalian target of rapamycin (mTOR ) is involved in the neuronal differentiation of neural progenitors induced by insulin
357. Maternal Protein restriction in the Rat inhibit s Placental insulin , mTOR , and STAT3 Signaling and Down-Regulates Placental Amino Acid Transporters
358. Hepatitis C Virus Activates the mTOR /S6K1 Signaling Pathway in inhibit ing IRS-1 Function for insulin Resistance
359. The insulin -like Growth Factor-I–mTOR Signaling Pathway Induces the Mitochondrial Pyrimidine Nucleotide Carrier to Promote Cell Growth
360. insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibit or temsirolimus in patients with metastatic adrenocortical carcinoma
361. Glucose phosphorylation is required for insulin -dependent mTOR signalling in the heart
362. Activation of mTOR /p70S6 kinase by ANG II inhibit s insulin -stimulated endothelial nitric oxide synthase and vasodilation
363. mTOR inhibit ion with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
364. Amino acids are necessary for the insulin -induced activation of mTOR /S6K1 signaling and protein synthesis in healthy and insulin resistant human skeletal muscle
365. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice
366. insulin -Like Growth Factor I-Mediated Skeletal Muscle Hypertrophy Is Characterized by Increased mTOR -p70S6K Signaling without Increased Akt Phosphorylation
367. The Pi3k /Akt/mTOR signaling pathway mediates insulin -like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells
368. insulin ‐like growth factor‐1 (IGF‐1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR ) pathway
369. mTOR Complex 2 Regulates Proper Turnover of insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8
370. Both Wnt and mTOR signaling pathways are involved in insulin -stimulated proto-oncogene expression in intestinal cells
371. Zinc stimulates the activity of the insulin – and nutrient-regulated protein kinase mTOR
372. Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (AMPK /mTOR ) and c-Jun N-terminal Kinase/insulin Receptor Substrate 1 (JNK/IRS1) Pathways
373. Role of the PI3-kinase/mTOR pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver
374. Exercise training reduces insulin resistance and upregulates the mTOR /p70S6k pathway in cardiac muscle of diet‐induced obesity rats
375. Leucine Activates Pancreatic Translational Machinery in Rats and Mice through mTOR Independently of CCK and insulin
376. Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-insulin –like Growth Factor I Receptor Monoclonal Antibody
377. insulin Potentiates Ca2+ Signaling and Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Induced by Gq Protein-Coupled Receptor Agonists through an mTOR -Dependent Pathway
378. insulin -induced stimulation of JNK and the PI 3-kinase/mTOR pathway leads to phosphorylation of serine 318 of IRS-1 in C2C12 myotubes
379. Tissue-Specific Responses of IGF-1/insulin and mTOR Signaling in calorie Restricted Rats
380. mTOR C2 promotes type I insulin -like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
381. insulin -like growth factor-I inhibit s dexamethasone-induced proteolysis in cultured L6 myotubes through Pi3k /Akt/GSK-3β and Pi3k /Akt/mTOR -dependent mechanisms
382. The role of AMPK /mTOR /S6K1 signaling axis in mediating the physiological process of exercise-induced insulin sensitization in skeletal muscle of C57BL/6 mice
383. Glucose Induces Mouse β-Cell Proliferation via IRS2, MTOR, and Cyclin D2 but Not the Insulin Receptor.
384. insulin Promotes Glucose Consumption via Regulation of miR-99a/mTOR /PKM2 Pathway
385. insulin -induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR : studies on the function of Ser675 and Ser907
386. Protein Ingestion Induces Muscle Insulin Resistance Independent of Leucine-Mediated mTOR Activation.
387. Salmonella enterica Typhimurium infection causes metabolic changes in chicken muscle involving AMPK , fatty acid and insulin /mTOR signaling
388. inhibit ion of the mTOR /p70S6K pathway is not involved in the insulin -sensitizing effect of AMPK on cardiac glucose uptake
389. Acute mTOR inhibit ion induces insulin resistance and alters substrate utilization in vivo
390. Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells
391. Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats
392. Implication of RICTOR in the mTOR inhibit or-mediated induction of insulin -like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
393. Cardiac overexpression of insulin -like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: Roles of Akt, mTOR , GSK3β, and PTEN
394. Palmitate Induced insulin Resistance by PKCtheta-Dependent Activation of mTOR /S6K Pathway in C2C12 Myotubes
395. insulin fails to enhance mTOR phosphorylation, mitochondrial protein synthesis, and ATP production in human skeletal muscle without amino acid replacement
396. Mechanistic target of rapamycin (mTOR ): a point of convergence in the action of insulin /IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells
397. Raptor Binds the SAIN (Shc and IRS-1 NPXY Binding) Domain of insulin Receptor Substrate-1 (IRS-1) and Regulates the Phosphorylation of IRS-1 at Ser-636/639 by mTOR
398. Quantification of the effect of amino acids on an integrated mTOR and insulin signaling pathway
399. The Mechanism of insulin -stimulated 4E-BP Protein Binding to Mammalian Target of Rapamycin (mTOR ) Complex 1 and Its Contribution to mTOR Complex 1 Signaling
400. Activation of placental insulin and mTOR signaling in a mouse model of maternal obesity associated with fetal overgrowth
401. Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling
402. Adipocyte-specific deletion of mTOR inhibit s adipose tissue development and causes insulin resistance in mice
403. insulin inhibit ion of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation
404. PKCζ Is Essential for Pancreatic β-Cell Replication During Insulin Resistance by Regulating mTOR and Cyclin-D2.
405. Cardamonin Ameliorates insulin Resistance Induced by High insulin and High Glucose through the mTOR and Signal Pathway
406. inhibit ion of PI-3 kinase/Akt/mTOR , but not calcineurin signaling, reverses insulin -like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function
407. Evodiamine inhibit s insulin -Stimulated mTOR -S6K Activation and IRS1 Serine Phosphorylation in Adipocytes and Improves Glucose Tolerance in Obese/Diabetic Mice
408. insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1
409. mTOR -Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1
410. The inhibit ion of insulin -stimulated Proliferation of Vascular Smooth Muscle Cells by Rosiglitazone Is Mediated by the Akt-mTOR -P70S6K Pathway
411. insulin regulation of hepatic insulin -like growth factor-binding protein-1 (IGFBP-1) gene expression and mammalian target of rapamycin (mTOR ) signalling is impaired by the presence of hydrogen peroxide
412. Anthocyanin-rich mulberry fruit improves insulin resistance and protects hepatocytes against oxidative stress during hyperglycemia by regulating AMPK /ACC/mTOR pathway
413. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer’s disease
414. Impaired overload-induced hypertrophy is associated with diminished mTOR signaling in insulin -resistant skeletal muscle of the obese Zucker rat
415. Anti-inflammatory action of insulin via induction of Gadd45-β transcription by the mTOR signaling pathway
416. In Human Endothelial Cells Amino Acids Inhibit Insulin-induced Akt and ERK1/2 Phosphorylation by an mTOR-dependent Mechanism
417. Activation of the hexosamine pathway leads to phosphorylation of IRS-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mTOR insulin biosynthetic pathway in RIN pancreatic {beta}-cells
418. Essential Amino Acids Improve insulin Activation of Akt/mTOR Signaling in Soleus Muscle of Aged Rats
419. Akt/mTOR Role in Human Foetoplacental Vascular insulin Resistance in Diseases of Pregnancy
420. Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor
421. The Regulation of Lipid Deposition by insulin in Goose Liver Cells Is Mediated by the Pi3k -AKT-mTOR Signaling Pathway
422. Pectic Bee Pollen Polysaccharide from Rosa rugosa Alleviates Diet-Induced Hepatic Steatosis and insulin Resistance via Induction of AMPK /mTOR -Mediated Autophagy
423. Reduction of insulin signalling pathway IRS‐1/IRS‐2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid‐treated rats
424. Flavanol‐rich lychee fruit extract alleviates diet‐induced insulin resistance via suppressing mTOR /SREBP‐1 mediated lipogenesis in liver and restoring insulin signaling in skeletal muscle
425. insulin -like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the Pi3k /Akt/mTOR signaling pathway
426. Melanocortin-4 receptor activation promotes insulin -stimulated mTOR signaling
427. Heparin-Binding EGF-Like Growth Factor (HB-EGF) Mediates 5-HT-Induced insulin Resistance Through Activation of EGF Receptor-ERK1/2-mTOR Pathway
428. Zinc stimulates glucose consumption by modulating the insulin signaling pathway in L6 myotubes: essential roles of Akt–GLUT4, GSK3β and mTOR –S6K1
429. Amino acid-sensing mTOR signaling is involved in modulation of lipolysis by chronic insulin treatment in adipocytes
430. Overexpression of Kinase-Dead mTOR Impairs Glucose Homeostasis by Regulating Insulin Secretion and Not β-Cell Mass.
431. Combination of the mammalian target of rapamycin (mTOR ) inhibit or everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibit or NVP-AEW-541: A mechanistic based anti-tumor strategy
432. Exercise improves skeletal muscle insulin resistance without reduced basal mTOR /S6K1 signaling in rats fed a high-fat diet
433. insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the Pi3k /mTOR pathway
434. The dual targeting of insulin and insulin -like growth factor 1 receptor enhances the mTOR inhibit or-mediated antitumor efficacy in hepatocellular carcinoma
435. insulin activation of vacuolar protein sorting 34 mediates localized phosphatidylinositol 3-phosphate production at lamellipodia and activation of mTOR /S6K1
436. Attenuation of insulin resistance in rats by agmatine: role of SREBP-1c, mTOR and GLUT-2
437. mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine307 residues after burn
438. Development of a model describing regulation of casein synthesis by the mammalian target of rapamycin (mTOR ) signaling pathway in response to insulin , amino acids, and acetate
439. Judicious Toggling of mTOR Activity to Combat insulin Resistance and cancer : Current Evidence and Perspectives
440. Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer’s disease
441. insulin Stimulates Goose Liver Cell Growth by Activating Pi3k -AKT-mTOR Signal Pathway
442. The effects of amino acids on glucose metabolism of isolated rat skeletal muscle are independent of insulin and the mTOR /S6K pathway
443. Exercise and dietary change ameliorate high fat diet induced obesity and insulin resistance via mTOR signaling pathway
444. insulin -like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibit ion of the mTOR pathway in prostate cancer
445. insulin Increases Sestrin 2 Content by Reducing Its Degradation through the Pi3k /mTOR Signaling Pathway
446. calorie restriction : Decelerating mTOR -driven Aging from cells to organisms (including humans)
447. mTOR and autophagy in normal brain Aging and caloric restriction ameliorating age-related cognition deficits
448. Effects of Intermittent and Chronic calorie restriction on Mammalian Target of Rapamycin (mTOR ) and IGF-I Signaling Pathways in Mammary Fat Pad Tissues and Mammary Tumors
449. Effect of caloric restriction on the SIRT1/mTOR signaling pathways in senile mice
450. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow Aging . Coincidences with calorie restriction and mTOR inhibit ion
451. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR
452. Systematic gene expression profile of hypothalamus in calorie -restricted mice implicates the involvement of mTOR signaling in neuroprotective activity
453. mTOR signaling and ubiquitin-proteosome gene expression in the preservation of fat free mass following high protein, calorie restricted weight loss
454. fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling
455. Muscle Wasting in fasting Requires Activation of NF-κB and inhibit ion of AKT/Mechanistic Target of Rapamycin (mTOR ) by the Protein Acetylase, GCN5
456. fasting glucose and triglycerides as biomarkers of mTOR inhibit ion, evidence of a categorical response.
457. mTOR C1 controls fasting -induced ketogenesis and its modulation by ageing
458. The ketogenic diet inhibit s the mammalian target of rapamycin (mTOR ) pathway
459. Rapamycin passes the torch: a new generation of mTOR inhibit ors
460. Pi3k /AKT/mTOR inhibit ors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
461. Next-generation mTOR inhibit ors in clinical oncology: how pathway complexity informs therapeutic strategy
462. mTOR inhibit ors: An overview
463. Updates of mTOR inhibit ors
464. PIK3CA Mutations in Patients with Advanced cancer s Treated with Pi3k /AKT/mTOR Axis inhibit ors
465. Enhanced radiation damage of tumor vasculature by mTOR inhibit ors
466. AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR ) inhibit ors by Regulating Cyclin D1 and c-myc Expression
467. Ras/Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR inhibit ors: Rationale and Importance to inhibit ing These Pathways in Human Health
468. Picking the Point of inhibit ion: A Comparative Review of Pi3k /AKT/mTOR Pathway inhibit ors
469. Targeting the mTOR kinase domain: the second generation of mTOR inhibit ors
470. Pilot study of the combination of EGFR and mTOR inhibit ors in recurrent malignant gliomas
471. mTOR Signaling, Function, Novel inhibit ors, and Therapeutic Targets
472. Strategies for the management of adverse events associated with mTOR inhibit ors
473. mTOR inhibit ors-induced proteinuria: mechanisms, significance, and management
474. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
475. Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR ) inhibit ors: Effects on mTOR C1 and Akt Signaling Lead to Improved Survival and Function
476. Combinations of BRAF, MEK, and Pi3k /mTOR inhibit ors Overcome Acquired Resistance to the BRAF inhibit or GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
477. Assessing PIK3CA and PTEN in Early-Phase Trials with Pi3k /AKT/mTOR inhibit ors
478. Pi3k and mTOR inhibit ors — a new generation of targeted anticancer agents
479. mTOR inhibit or/proliferation signal inhibit ors: entering or leaving the field?
480. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
481. Predicted mechanisms of resistance to mTOR inhibit ors
482. mTOR inhibit ors in Tuberous Sclerosis Complex
483. The role of mTOR inhibitors in the management of posttransplant malignancy.
484. Pushing the Envelope in the mTOR Pathway: The Second Generation of inhibit ors
485. IRS-1: Auditing the effectiveness of mTOR inhibit ors
486. mTOR inhibit ors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
487. mTOR inhibit ors in Polycystic Kidney Disease
488. mTOR inhibit ors in Advanced Renal Cell Carcinoma
489. inhibit ors of mTOR
490. mTOR inhibit ors in renal cell carcinoma
491. The pleiotropic effects of mTOR inhibit ors.
492. The emerging safety profile of mTOR inhibit ors, a novel class of anticancer agents
493. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
494. Rapamycin and mTOR kinase inhibit ors
495. Current development of the second generation of mTOR inhibit ors as anticancer agents
496. Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR ) inhibit ors
497. Potent antifibrotic activity of mTOR inhibit ors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
498. Replacing calcineurin inhibit ors with mTOR inhibit ors in children
499. Aspects of mTOR biology and the use of mTOR inhibit ors in non-Hodgkin’s lymphoma
500. Differentiating mTOR inhibit ors in renal cell carcinoma
501. Mammalian target of rapamycin (mTOR ) inhibit ors
502. mTOR inhibit ors Alone and in Combination with JAK2 inhibit ors Effectively inhibit Cells of Myeloproliferative Neoplasms
503. Targeted inhibit ion of mTOR C1 and mTOR C2 by active-site mTOR inhibit ors has cytotoxic effects in T-cell acute lymphoblastic leukemia
504. Increased Incidence of Angioedema with ACE inhibit ors in Combination with mTOR inhibit ors in Kidney Transplant Recipients
505. mTOR inhibit ors and their clinical application in cervical, endometrial and ovarian cancer s: A critical review
506. Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR ) inhibit ors and Characterization of Their Binding Kinetics
507. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibit ors in human ovarian carcinoma
508. Review of combination therapy with mTOR inhibit ors and tacrolimus minimization after transplantation
509. Therapeutic polymeric nanoparticles with mTOR inhibit ors and methods of making and using same
510. Pneumonitis associated with mTOR inhibit ors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome
511. MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR inhibit ors
512. Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR inhibit ors in Metastatic Renal Cell Carcinoma
513. Updating progress in sarcoma therapy with mTOR inhibit ors
514. mTOR inhibit ors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma
515. Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR inhibit ors in Neuroendocrine Tumor Therapy
516. Mammalian Target of Rapamycin (mTOR ) inhibit ors
517. Synergic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibit ors on pancreatic cancer cells
518. Metabolic complications with the use of mTOR inhibit ors for cancer therapy
519. A critical review of mTOR inhibit ors and epilepsy: from basic science to clinical trials
520. mTOR inhibit ors in breast cancer : A systematic review
521. Biologic rationale and clinical activity of mTOR inhibit ors in gynecological cancer
522. Defining biomarkers to predict sensitivity to Pi3k /Akt/mTOR pathway inhibit ors in breast cancer
523. Comparison of the effects of the Pi3k /mTOR inhibit ors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
524. Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR inhibit ors for the Treatment of cancer
525. Focus on mTOR inhibit ors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes
526. Preclinical evaluation of dual Pi3k –mTOR inhibit ors and histone deacetylase inhibit ors in head and neck squamous cell carcinoma
527. Induction of autophagy with catalytic mTOR inhibit ors reduces huntingtin aggregates in a neuronal cell model
528. Comparative Analysis of Adverse Events Requiring Suspension of mTOR inhibit ors: Everolimus versus Sirolimus
529. Mammalian target of rapamycin (mTOR ) inhibit ors slow skin carcinogenesis, but impair wound healing
530. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibit ors
531. mTOR pathway and mTOR inhibit ors in head and neck cancer
532. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress : interactions with mTOR inhibit ors
533. mTOR inhibit ors at a Glance
534. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibit ors? A systematic review of randomized controlled trials
535. Clinical development of mTOR inhibitors in breast cancer
     
536. inhibit ors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation
537. Incomplete inhibit ion of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibit ors
538. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibit ors for malignancy. A meta-analysis of published trials
539. Cancer and mTOR Inhibitors in Transplant Recipients.
540. Antitumor activity of pimasertib, a selective MEK 1/2 inhibit or, in combination with Pi3k /mTOR inhibit ors or with multi‐targeted kinase inhibit ors in pimasertib‐resistant human lung and colorectal cancer cells
541. The Role of mTOR inhibit ors in Liver Transplantation: Reviewing the Evidence
542. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibit ors of the mammalian target of rapamycin (mTOR ): Optimization of the 1-substituent
543. [Pi3k -AKT-mTOR pathway inhibit ors].
544. inhibit ion of Pi3k -Akt-mTOR Signaling in Glioblastoma by mTOR C1/2 inhibit ors
545. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
546. Differentiating the mTOR inhibit ors everolimus and sirolimus in the treatment of tuberous sclerosis complex
547. Treatment outcome with mTOR inhibit ors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
548. mTOR inhibit ors: Do They Help Preserve Renal Function?
549. mTOR , p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and Pi3k /mTOR inhibit ors in human bronchial carcinoids
550. The therapeutic potential of mTOR inhibit ors in breast cancer
551. Pi3k -AKT-mTOR inhibit ors in breast cancer s: From tumor cell signaling to clinical trials
552. Maximizing the clinical outcome with mTOR inhibit ors in the renal transplant recipient: defining the role of calcineurin inhibit ors
553. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7 Ralpha signaling.
554. Catalytic mTOR inhibit ors can overcome intrinsic and acquired resistance to allosteric mTOR inhibit ors
555. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.
556. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
557. Role of mTOR inhibit ors in epilepsy treatment
558. “Overcoming breast cancer drug resistance with mTOR inhibit ors”. Could it be a myth or a real possibility in the short-term future?
559. Safety of mTOR inhibit ors in adult solid organ transplantation
560. mTOR inhibit ors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma
561. Synergistic antiproliferative effect of mTOR inhibit ors in combination with 5‐fluorouracil in scirrhous gastric cancer
562. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR ) inhibit ors
563. mTOR inhibit ors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibit or lapatinib (Tykerb®)
564. Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR inhibit ors
565. mTOR inhibit ors as a new therapeutic option for epilepsy
566. mTOR inhibit ors in the management of hormone receptor-positive breast cancer : the latest evidence and future directions
567. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
568. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibit ors: Discovery of highly potent and selective analogs with improved human microsomal stability
569. FBXW7 Mutations in Patients with Advanced cancer s: Clinical and Molecular Characteristics and Outcomes with mTOR inhibit ors
570. Use of APO2L/TRAIL with mTOR inhibit ors in the treatment of glioblastoma multiforme
571. Discovery and Assembly-Line Biosynthesis of the Lymphostin Pyrroloquinoline Alkaloid Family of mTOR inhibit ors in Salinispora Bacteria
572. Benchmarking effects of mTOR , Pi3k , and dual Pi3k /mTOR inhibit ors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
573. The role of mTOR inhibit ors for treatment of sarcomas
574. Combining mTOR inhibit ors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination
575. mTOR inhibit ors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation
576. inhibit ors of Pi3k /Akt and/or mTOR inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 inhibit or and Interferon,
577. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibit ors: current and emerging therapeutic options
578. Combining mTOR inhibit ors with Chemotherapy and Other Targeted Therapies in Advanced Breast cancer : Rationale, Clinical Experience, and Future Directions
579. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibit ors
580. inhibit ion of mTOR Pathway Sensitizes Acute Myeloid Leukemia Cells to Aurora inhibit ors by Suppression of Glycolytic Metabolism
581. Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR inhibit ors
582. mTOR inhibit ors counteract tamoxifen-induced activation of breast cancer stem cells
583. Resistance to mTOR Kinase inhibit ors in Lymphoma Cells Lacking 4EBP1
584. The inhibit ion of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibit ors
585. mTOR inhibit ors in pediatric kidney transplantation
586. mTOR inhibit ors and dyslipidemia in transplant recipients: A cause for concern?
587. The Role of mTOR inhibit ors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions
588. mTOR inhibit ors in advanced breast cancer : Ready for prime time?
589. Innovations therapy: mammalian target of rapamycin (mTOR ) inhibit ors for the treatment of neuroendocrine tumors
590. mTOR inhibit ors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation
591. Therapeutic activity of mTOR inhibit ors in mantle cell lymphoma: Clues but no clear answers
592. Use of mTOR inhibit ors in chronic heart transplant recipients with renal failure: Calcineurin-inhibit ors conversion or minimization?
593. Is There a Role for Proliferation Signal/mTOR inhibit ors in the Prevention and Treatment of De Novo Malignancies After Heart Transplantation? Lessons Learned From Renal Transplantation and Oncology
594. Development of ATP-Competitive mTOR inhibit ors
595. The role of mTOR inhibit ors in the inhibit ion of growth and cortisol secretion in human adrenocortical carcinoma cells
596. Fused bicyclic mTOR inhibit ors
597. mTOR inhibit ors radiosensitize PTEN‐deficient non‐small‐cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
598. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibit ors
599. Dual Pi3k /mTOR inhibit ors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic cancer Cells through Suppression of mTOR C2
600. Potential of mTOR inhibit ors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
601. Identification of 2-oxatriazines as highly potent pan-Pi3k /mTOR dual inhibit ors
602. Recent advances in the development of selective, ATP-competitive inhibit ors of mTOR .
603. ATP-Competitive inhibit ors of mTOR : An Update
604. Can mTOR inhibit ors reduce the risk of late kidney allograft failure?
605. inhibit ion of mTOR pathway by everolimus cooperates with EGFR inhibit ors in human tumours sensitive and resistant to anti-EGFR drugs
606. Everolimus and mTOR inhibit ors in liver transplantation: Opening the “box”
607. Skin cancer in solid organ transplant recipients: are mTOR inhibit ors a game changer?
608. mTOR inhibit ors Control the Growth of EGFR Mutant Lung cancer Even after Acquiring Resistance by HGF
609. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibit ors
610. The pros and the cons of mTOR inhibit ors in kidney transplantation
611. Ras/Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR Cascade inhibit ors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
612. The mTOR kinase inhibit ors polarize glioma-activated microglia to express a M1 phenotype
613. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibit ors
614. Ophthalmic compositions comprising calcineurin inhibit ors or mTOR inhibit ors
615. Management of side effects of mTOR inhibit ors in tuberous sclerosis patients
616. Clinical efficacy of mTOR inhibit ors in solid tumors: a systematic review
617. inhibit ors of mTOR overcome drug resistance from topoisomerase II inhibit ors in solid tumors
618. mTOR inhibit ors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours
619. Mammalian target of rapamycin inhibit ors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin -like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
620. mTOR inhibit ors in hematologic malignancies.
621. Thymoma Patients Treated in a Phase I Clinic at MD Anderson cancer Center: Responses to mTOR inhibit ors and Molecular Analyses
622. inhibit ion of autophagy sensitizes malignant pleural mesothelioma cells to dual Pi3k /mTOR inhibit ors
623. mTOR inhibit ors in Castration-Resistant Prostate cancer : A Systematic Review
624. Gerosuppression by pan-mTOR inhibit ors
625. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death
626. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress : potential role in obesity
627. Pi3k /Akt and mTOR /p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress -induced apoptosis
628. Bridges between mitochondrial oxidative stress , ER stress and mTOR signaling in pancreatic β cells
629. Mammalian Target of Rapamycin (mTOR ) inhibit ion with Rapamycin Improves Cardiac Function in Type 2 Diabetic Mice
     POTENTIAL ROLE OF ATTENUATED oxidative stress AND ALTERED CONTRACTILE PROTEIN EXPRESSION
630. Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress -mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
631. inhibit ion of Pi3k /AKT/mTOR axis disrupts oxidative stress -mediated survival of melanoma cells
632. Melatonin represses oxidative stress ‐induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibit ion of Ras
633. Tuberous Sclerosis Complex Activity Is Required to Control Neuronal Stress Responses in an mTOR -Dependent Manner
634. Resveratrol exerts antidepressant properties in the chronic unpredictable mild stress model through the regulation of oxidative stress and mTOR pathway in the rat hippocampus and prefrontal cortex
635. Salvianolic acid B protects human endothelial progenitor cells against oxidative stress -mediated dysfunction by modulating Akt/mTOR /4EBP1, p38 MAPK/ATF2, and ERK1/2 signaling pathways
636. Particulate matter exposure induces the autophagy of macrophages via oxidative stress -mediated Pi3k /AKT/mTOR pathway
637. Insights for oxidative stress and mTOR Signaling in Myocardial Ischemia/Reperfusion Injury under diabetes
638. Neuroprotection Through Rapamycin-Induced Activation of Autophagy and Pi3k /Akt1/mTOR /CREB Signaling Against Amyloid-β-Induced oxidative stress , Synaptic/Neurotransmission Dysfunction, and Neurodegeneration in Adult Rats
639. Radiation persistently promoted oxidative stress , activated mTOR via Pi3k /Akt, and downregulated autophagy pathway in mouse intestine
640. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein
641. Glucose Regulation of Load‐Induced mTOR Signaling and ER Stress in Mammalian Heart
642. Alpha-melanocyte stimulating hormone protects retinal pigment epithelium cells from oxidative stress through activation of melanocortin 1 receptor–Akt–mTOR signaling
643. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death
644. Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH‐SY5Y cells
645. oxidative stress plays a key role in butyrate-mediated autophagy via Akt/mTOR pathway in hepatoma cells
646. Induction of autophagy by salidroside through the AMPK –mTOR pathway protects vascular endothelial cells from oxidative stress -induced apoptosis
647. Tumor Cells Switch to Mitochondrial Oxidative Phosphorylation under Radiation via mTOR -Mediated Hexokinase II inhibit ion – A Warburg-Reversing Effect
648. Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and oxidative stress via mTOR /eNOS Pathway
649. The role of CAPE in Pi3k /AKT/mTOR activation and oxidative stress on testis torsion
650. Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway
651. mTOR , AMPK , and Sirt1: Key Players in Metabolic Stress Management
652. Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
653. The Role of AKT/mTOR Pathway in Stress Response to UV-Irradiation: Implication in Skin Carcinogenesis by Regulation of Apoptosis, Autophagy and Senescence
654. Growth Control Under Stress: mTOR Regulation through the REDD1-TSC Pathway
655. Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate
656. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress -mediated mTOR inhibit ion
657. Molecular mechanisms of mTOR regulation by stress
658. α-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibit ion of Akt/mTOR pathway
659. Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating Pi3k /Akt/mTOR mediated BDNF/TrkB pathway
660. An α-Acetoxy-Tirucallic Acid Isomer inhibit s Akt/mTOR Signaling and Induces oxidative stress in Prostate cancer Cells
661. Lp-PLA2 silencing protects against ox-LDL-induced oxidative stress and cell apoptosis via Akt/mTOR signaling pathway in human THP1 macrophages
662. Endosulfan induces autophagy and endothelial dysfunction via the AMPK /mTOR signaling pathway triggered by oxidative stress
663. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibit ory modulation
664. Alcohol Dehydrogenase Protects against Endoplasmic Reticulum Stress-Induced Myocardial Contractile Dysfunction via Attenuation of oxidative stress and Autophagy: Role of PTEN-Akt-mTOR Signaling
665. Metformin-induced protection against oxidative stress is associated with AKT/mTOR restoration in PC12 cells
666. Proteasome inhibit ors Activate Autophagy Involving inhibit ion of Pi3k -Akt-mTOR Pathway as an Anti-Oxidation Defense in Human RPE Cells
667. FNDC5 Alleviates Hepatosteatosis by Restoring AMPK/mTOR-Mediated Autophagy, Fatty Acid Oxidation, and Lipogenesis in Mice
668. mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN
669. Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent Pi3k /Akt/mTOR Signaling Pathway
670. The Pi3k /Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress
671. Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by Pi3k and mTOR inhibit ors in acute myeloid leukaemia cells
672. Aspirin-triggered resolvin D1 inhibit s TGF-β1-induced EMT through the inhibit ion of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress
673. Rapamycin Confers Neuroprotection against Colistin-Induced oxidative stress , Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR /Akt/CREB Signaling Pathways
674. The effects of melatonin on oxidative stress and prevention of primordial follicle loss via activation of mTOR pathway in the rat ovary
675. inhibit ion of Rac1 ameliorates neuronal oxidative stress damage via reducing Bcl-2/Rac1 complex formation in mitochondria through Pi3k /Akt/mTOR pathway
676. Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways
677. Aurora kinase A suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells
678. Subtoxic concentrations of benzo[a]pyrene induce metabolic changes and oxidative stress in non-activated and affect the mTOR pathway in activated Jurkat T cells
679. TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway
680. Melatonin Combined with Endoplasmic Reticulum Stress Induces Cell Death via the Pi3k /Akt/mTOR Pathway in B16F10 Melanoma Cells
681. Thioredoxin-1 maintains mechanistic target of rapamycin (mTOR ) function during oxidative stress in cardiomyocytes
682. Glucocorticoids Modulate the mTOR Pathway in the Hippocampus: Differential Effects Depending on Stress History
683. Spironolactone promotes autophagy via inhibit ing Pi3k /AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress
684. Honokiol induces autophagy of neuroblastoma cells through activating the Pi3k /Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration
685. Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of rapamycin into prefrontal cortex
686. Global Proteomics Revealed Klebsiella pneumoniae Induced Autophagy and oxidative stress in Caenorhabditis elegans by inhibit ing Pi3k /AKT/mTOR Pathway during Infection
687. Gold nanoparticles reduce high glucose-induced oxidative-nitrosative stress regulated inflammation and apoptosis via tuberin-mTOR /NF-κB pathways in macrophages
688. oxidative stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer’s Disease
689. Osmotic Stress Regulates Mammalian Target of Rapamycin (mTOR ) Complex 1 via c-Jun N-terminal Kinase (JNK)-mediated Raptor Protein Phosphorylation
690. The mTOR promotes oxidative stress -induced apoptosis of mesangial cells in diabetic nephropathy
691. Autophagy protects gastric mucosal epithelial cells from ethanol-induced oxidative damage via mTOR signaling pathway
692. AKT/mTOR as novel targets of polyphenol piceatannol possibly contributing to inhibit ion of proliferation of cultured prostate cancer cells
693. Targeting mTOR signaling by polyphenol s: A new therapeutic target for ageing
694. Protective effects of a green tea polyphenol , epigallocatechin-3-gallate, against sevoflurane-induced neuronal apoptosis involve regulation of CREB/BDNF/TrkB and Pi3k /Akt/mTOR signalling pathways in neonatal mice
695. Sorghum polyphenol suppresses the growth as well as metastasis of colon cancer xenografts through co-targeting jak2/STAT3 and Pi3k /Akt/mTOR pathways
696. Curculigoside and polyphenol -rich ethyl acetate fraction of Molineria latifolia rhizome improved glucose uptake via potential mTOR /AKT activated GLUT4 translocation
697. inhibit ion of Akt/mTOR Signaling by the Dietary flavonoid Fisetin
698. flavonoid myricetin inhibit s TNF-α-stimulated production of inflammatory mediators by suppressing the Akt, mTOR and NF-κB pathways in human keratinocytes
699. DUAL inhibit ION OF Pi3k /AKT AND mTOR SIGNALING IN HUMAN NON-SMALL CELL LUNG cancer CELLS BY A DIETARY flavonoid FISETIN
700. Rutin, A Natural flavonoid Protects PC12 Cells Against Sodium Nitroprusside-Induced Neurotoxicity Through Activating Pi3k /Akt/mTOR and ERK1/2 Pathway
701. flavonoid s inhibit cell proliferation and induce apoptosis and autophagy through downregulation of Pi3k γ mediated Pi3k /AKT/mTOR /p70S6K/ULK signaling pathway in human breast cancer cells
702. Luteolin, a natural flavonoid , inhibit s methylglyoxal induced apoptosis via the mTOR /4E-BP1 signaling pathway
703. Abstract 1586: Tumor regression in a 3-D melanoma model by the dietary flavonoid fisetin is associated with inhibit ion of Akt/mTOR signaling
704. [Effect of total flavonoid s in Scutellaria barbata in mediating autophagy in tumor cells via Pi3k /AKT/mTOR pathway].
705. Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the Pi3k /Akt/mTOR signaling pathway
706. LZ205, a newly synthesized flavonoid compound, exerts anti-inflammatory effect by inhibit ing M1 macrophage polarization through regulating Pi3k /AKT/mTOR signaling pathway
707. Anti-inflammatory effects of water extract of Taraxacum mongolicum hand.-Mazz on lipopolysaccharide-induced inflammation in acute lung injury by suppressing Pi3k /Akt/mTOR signaling pathway
708. Ethanolic Ginkgo biloba leaf extract prevents renal fibrosis through Akt/mTOR signaling in diabetic nephropathy
709. Lactobacillus casei extract Induces Apoptosis in Gastric cancer by inhibit ing NF-κB and mTOR -Mediated Signaling
710. Huaier extract Induces Autophagic Cell Death by inhibit ing the mTOR /S6K Pathway in Breast cancer Cells
711. Rosemary extract reduces Akt/mTOR /p70S6K activation and inhibit s proliferation and survival of A549 human lung cancer cells
712. PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibit s growth of human pancreatic cancer via targeting the Pi3k /mTOR pathway
713. Mechanism of Chemoprevention against Colon Cancer Cells Using Combined Gelam Honey and Ginger Extract via mTOR and Wnt/β-catenin Pathways.
714. Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibit ions in renal cancer cells
715. Arecoline and the 30–100 kDa fraction of areca nut extract differentially regulate mTOR and respectively induce apoptosis and autophagy: a pilot study
716. Ethanol extract of Remotiflori radix induces endoplasmic reticulum stress-mediated cell death through AMPK /mTOR signaling in human prostate cancer cells
717. An enzymatically fortified ginseng extract inhibit s proliferation and induces apoptosis of KATO3 human gastric cancer cells via modulation of Bax, mTOR , PKB and IκBα
718. Celastrus Orbiculatusextract could inhibit human colorectal carcinoma HT-29 cells metastasis via suppression of the mTOR signaling pathway
719. Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling
720. Cell Cycle Arrest of extract from Artemisia annua Linné. Via Akt-mTOR Signaling Pathway in HCT116 Colon cancer Cells
721. Auraptene, a Major Compound of Supercritical Fluid extract of Phalsak (Citrus Hassaku Hort ex Tanaka), Induces Apoptosis through the Suppression of mTOR Pathways in Human Gastric cancer SNU-1 Cells
722. Centipeda minima (Ebushicao) extract inhibit s Pi3k -Akt-mTOR signaling in nasopharyngeal carcinoma CNE-1 cells
723. extract from Astragalus membranaceus inhibit breast cancer cells proliferation via Pi3k /AKT/mTOR signaling pathway
724. Suppression of mTOR Signaling Pathways in Skeletal Muscle of Finishing Pigs by Increasing the Ratios of Ether extract and Neutral Detergent Fiber at the Expense of Starch in Iso-energetic Diets
725. Apocynum leaf extract inhibit s the progress of atherosclerosis in rats via the AMPK /mTOR pathway
726. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation
727. AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets
728. mTOR , AMPK , and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat
729. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
730. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK , and is involved in AMPK and mTOR signaling
731. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR
732. A possible linkage between AMP‐activated protein kinase (AMPK ) and mammalian target of rapamycin (mTOR ) signalling pathway
733. Selective activation of AMPK -PGC-1α or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation
734. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK
735. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.
736. The Role of AMPK and mTOR in Nutrient Sensing in Pancreatic β-Cells
737. Cross-Talk between AMPK and mTOR in Regulating Energy Balance
738. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibit ion of mTOR pathway and induction of autophagy
739. A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein diet-induced weight loss.
740. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR -dependent oncogenic mRNA translation
741. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: A crucial role of AMPK and mTOR pathways
742. Coordinated time-dependent modulation of AMPK /Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells
743. Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibit s incision-induced acute and chronic pain
744. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK /mTOR signaling pathway
745. Chondrocyte autophagy is stimulated by HIF-1 dependent AMPK activation and mTOR suppression
746. Differentiated mTOR but not AMPK signaling after strength vs endurance exercise in training‐accustomed individuals
747. Central Exercise Action Increases the AMPK and mTOR Response to Leptin
748. AMPK -Mediated inhibit ion of mTOR Kinase Is Circumvented during Immediate-Early Times of Human Cytomegalovirus Infection
749. Hypoxia-Induced Energy Stress inhibit s the mTOR Pathway by Activating an AMPK /REDD1 Signaling Axis in Head and Neck Squamous Cell Carcinoma
750. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK /mTOR pathway in high-fat diet-induced obese rats
751. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK /mTOR pathway
752. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK , Akt and mTOR pathways
753. Betulinic acid alleviates non-alcoholic fatty liver by inhibit ing SREBP1 activity via the AMPK –mTOR –SREBP signaling pathway
754. Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside
755. The AMPK stress response pathway mediates anoikis resistance through inhibit ion of mTOR and suppression of protein synthesis
756. Altered LKB1/AMPK /TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis
757. AMPK /mTOR -mediated inhibit ion of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell
758. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma
759. Porcine Circovirus Type 2 Induces Autophagy via the AMPK /ERK/TSC2/mTOR Signaling Pathway in PK-15 Cells
760. P2X7 Integrates Pi3k /AKT and AMPK -PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death
761. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK /mTOR /P70S6K signaling pathway
762. Autophagic cell death induced by resveratrol depends on the Ca2+/AMPK /mTOR pathway in A549 cells
763. Akt activation protects pancreatic beta cells from AMPK -mediated death through stimulation of mTOR
764. GLUT1 enhances mTOR activity independently of TSC2 and AMPK
765. Activation of AMPK and inactivation of Akt result in suppression of mTOR -mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson’s disease
766. NAD Blocks High Glucose Induced Mesangial Hypertrophy via Activation of the Sirtuins-AMPK –mTOR Pathway
767. ARG2 impairs endothelial autophagy through regulation of mTOR and PRKAA/AMPK signaling in advanced atherosclerosis
768. Resveratrol Enhances the Antitumor Effects of Temozolomide in Glioblastoma via ROS‐dependent AMPK ‐TSC‐mTOR Signaling Pathway
769. Feeding Uninvited Guests: mTOR and AMPK Set the Table for Intracellular Pathogens
770. 4-Nonylphenol induces apoptosis, autophagy and necrosis in Sertoli cells: Involvement of ROS-mediated AMPK /AKT-mTOR and JNK pathways
771. Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR , AMPK , and Erythropoietin
772. Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTOR C1 interaction
773. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK -activated mTOR inhibit ion
774. Quercetin Regulates Sestrin 2-AMPK –mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon cancer Cells
775. Glucose stimulates protein synthesis in skeletal muscle of neonatal pigs through an AMPK – and mTOR -independent process
776. A combination of four active compounds alleviates cerebral ischemia–reperfusion injury in correlation with inhibit ion of autophagy and modulation of AMPK /mTOR and JNK pathways
777. Reduced AMPK -ACC and mTOR signaling in muscle from older men, and effect of resistance exercise
778. l-Glutamine enhances enterocyte growth via activation of the mTOR signaling pathway independently of AMPK
779. Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK /mTOR /S6 and MAPK signaling
780. Antifungal drug itraconazole targets VDAC1 to modulate the AMPK /mTOR signaling axis in endothelial cells
781. Adiponectin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the AMPK /mTOR pathway
782. Tanshinone IIA Induces Autophagic Cell Death via Activation of AMPK and ERK and inhibit ion of mTOR and p70 S6K in KBM‐5 Leukemia Cells
783. Activation of autophagy via Ca2+-dependent AMPK /mTOR pathway in rat notochordal cells is a cellular adaptation under hyperosmotic stress
784. Mesenchymal stem cells promote colorectal cancer progression through AMPK /mTOR -mediated NF-κB activation
785. Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung cancer Cells by Repressing mTOR via AMPK Activation and Pi3k /Akt inhibit ion
786. FK866-induced NAMPT inhibit ion activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells
787. Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling
788. Berberine induces autophagy in glioblastoma by targeting the AMPK /mTOR /ULK1-pathway
789. A Novel Dual AMPK Activator/mTOR inhibit or inhibit s Thyroid cancer Cell Growth
790. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK /mTOR signaling pathway
791. Activation of Autophagic Flux against Xenoestrogen Bisphenol-A-induced Hippocampal Neurodegeneration via AMP kinase (AMPK )/Mammalian Target of Rapamycin (mTOR ) Pathways
792. Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK –mTOR pathway
793. miR-124 regulates cell apoptosis and autophagy in dopaminergic neurons and protects them by regulating AMPK /mTOR pathway in Parkinson’s disease
794. Effects of AMP-activated protein kinase (AMPK ) signaling and essential amino acids on mammalian target of rapamycin (mTOR ) signaling and protein synthesis rates in mammary cells
795. Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: A response associated with up-regulation of Akt/mTOR and AMPK activation
796. GYY4137, a novel hydrogen sulfide-releasing molecule, likely protects against high glucose-induced cytotoxicity by activation of the AMPK /mTOR signal pathway in H9c2 cells
797. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK -dependent and AMPK -independent inhibit ion of mTOR /p70S6K and ERK signaling
798. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells
799. Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK , AKT/mTOR pathways and neuroinflammatory cytokine release
800. Anti-Breast cancer Potential of Quercetin via the Akt/AMPK /Mammalian Target of Rapamycin (mTOR ) Signaling Cascade
801. Exendin-4 attenuates cardiac hypertrophy via AMPK /mTOR signaling pathway activation
802. A systems study reveals concurrent activation of AMPK and mTOR by amino acids
803. Salmonella Typhimurium disrupts Sirt1/AMPK checkpoint control of mTOR to impair autophagy
804. 2-Deoxy-d-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: Involvement of IGF-1R-regulated Akt/mTOR , MEK/ERK and LKB-1/AMPK signaling pathways
805. Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK , HIF and mTOR signaling
806. Strategies of Eradicating Glioma Cells: A Multi-Scale Mathematical Model with MiR-451-AMPK –mTOR Control
807. Phenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK /mTOR /p70s6k and MAPK/ERK Pathways in Breast cancer Cells
808. Sirt3 confers protection against neuronal ischemia by inducing autophagy: Involvement of the AMPK –mTOR pathway
809. hepaCAM and p-mTOR Closely Correlate in Bladder Transitional Cell Carcinoma and hepaCAM Expression inhibit s Proliferation via an AMPK /mTOR Dependent Pathway in Human Bladder cancer Cells
810. Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through Pi3k /AKT/mTOR and AMPK /SIRT1/FOXO3 pathways
811. Ox-Lp(a) transiently induces HUVEC autophagy via an ROS-dependent PAPR-1-LKB1–AMPK –mTOR pathway
812. Liraglutide relieves myocardial damage by promoting autophagy via AMPK –mTOR signaling pathway in zucker diabetic fatty rat
813. Hydrogen sulphide exacerbates acute pancreatitis by over‐activating autophagy viaAMPK /mTOR pathway
814. Palmitate activates mTOR /p70S6K through AMPK inhibit ion and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin
815. 4-Nonylphenol induces autophagy and attenuates mTOR -p70S6K/4EBP1 signaling by modulating AMPK activation in Sertoli cells
816. Autophagy Induction by Silibinin Positively Contributes to Its Anti-Metastatic Capacity via AMPK /mTOR Pathway in Renal Cell Carcinoma
817. Alisertib induces apoptosis and autophagy through targeting the AKT/mTOR /AMPK /p38 pathway in leukemic cells
818. Sestrin2, as a negative feedback regulator of mTOR , provides neuroprotection by activation AMPK phosphorylation in neonatal hypoxic-ischemic encephalopathy in rat pups
819. Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through inhibit ing B Cell Differentiation into Plasma Cells via Regulation of AMPK /mTOR /STAT3
820. Novel mechanism of reducing tumourigenesis: Upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibit ion
821. 20‐O‐β‐d‐Glucopyranosyl‐20(S)‐Protopanaxadiol Suppresses UV‐Induced MMP‐1 Expression Through AMPK ‐Mediated mTOR inhibit ion as a Downstream of the PKA‐LKB1 Pathway
822. Chitosan oligosaccharide suppresses tumor progression in a mouse model of colitis-associated colorectal cancer through AMPK activation and suppression of NF-κB and mTOR signaling
823. Role of Energy- and Nutrient-sensing KinasesAMP-activated Protein Kinase (AMPK ) andMammalian Target of Rapamycin (mTOR ) inAdipocyte Differentiation
824. Cyanidin-3-O-β-glucoside and protocatechuic acid activate AMPK /mTOR /S6K pathway and improve glucose homeostasis in mice
825. Mimulone-Induced Autophagy through p53-Mediated AMPK /mTOR Pathway Increases Caspase-Mediated Apoptotic Cell Death in A549 Human Lung cancer Cells
826. G9a inhibit ion Induces Autophagic Cell Death via AMPK /mTOR Pathway in Bladder Transitional Cell Carcinoma
827. Aβ peptide secretion is reduced by Radix Polygalae‑induced autophagy via activation of the AMPK /mTOR pathway
828. Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK /mTOR Pathway
829. Activation of autophagy through calcium-dependentAMPK /mTOR and PKChpathway causes activation of rathepatic stellate cells under hypoxic stress
830. Exogenous H2S Protects Against Diabetic Cardiomyopathy by Activating Autophagy via the AMPK /mTOR Pathway
831. PAS Kinase Is a Nutrient and Energy Sensor in Hypothalamic Areas Required for the Normal Function of AMPK and mTOR /S6K1
832. NQO1 Deficiency Leads Enhanced Autophagy in Cisplatin-Induced Acute Kidney Injury Through the AMPK /TSC2/mTOR Signaling Pathway
833. The AMPK Agonist PT1 and mTOR inhibit or 3HOI-BA-01 Protect Cardiomyocytes After Ischemia Through Induction of Autophagy
834. PARP-1 promotes autophagy via the AMPK /mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibit ion of autophagy contributes to the radiation sensitization of CNE-2 cells
835. Chronic Hypoxia-Induced Autophagy Aggravates the Neuropathology of Alzheimer’s Disease through AMPK –mTOR Signaling in the APPSwe/PS1dE9 Mouse Model
836. α‐enolase promotes tumorigenesis and metastasis via regulating AMPK /mTOR pathway in colorectal cancer
837. Macrophage migration inhibit ory factor promotes cardiac stem cell proliferation and endothelial differentiation through the activation of the Pi3k /Akt/mTOR and AMPK pathways
838. AMPK and mTOR : sensors and regulators of immunometabolic changes during Salmonella infection in the chicken
839. Polysaccharide from Fuzi Likely Protects Against Starvation-Induced Cytotoxicity in H9c2 Cells by Increasing Autophagy Through Activation of the AMPK /mTOR Pathway
840. Augmented β-Cell Function and Mass in Glucocorticoid-Treated Rodents Are Associated with Increased Islet Ir-β/AKT/mTOR and Decreased AMPK /ACC and AS160 Signaling
841. Vitamin D3 potentiates the growth inhibit ory effects of metformin in DU145 human prostate cancer cells mediated by AMPK /mTOR signalling pathway
842. Liraglutide attenuates the osteoblastic differentiation of MC3T3‑E1 cells by modulating AMPK /mTOR signaling
843. Cytoprotective effect of kaempferol against palmitic acid-induced pancreatic β-cell death through modulation of autophagy via AMPK /mTOR signaling pathway
844. polyphenol ics from mango (Mangifera indica L.) suppress breast cancer ductal carcinoma in situ proliferation through activation of AMPK pathway and suppression of mTOR in athymic nude mice
845. The antidepressant effects of ɑ-tocopherol are related to activation of autophagy via the AMPK /mTOR pathway
846. CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibit ion of AMPK /mTOR pathway
847. Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK /mTOR pathway in prostate cancer
848. Se‐Allylselenocysteine induces autophagy by modulating the AMPK /mTOR signaling pathway and epigenetic regulation of PCDH17 in human colorectal adenocarcinoma cells
849. Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK /mTOR mediated autophagic inhibit ion
850. Myocardial Ischemic Postconditioning Promotes Autophagy against Ischemia Reperfusion Injury via the Activation of the nNOS/AMPK /mTOR Pathway
851. Local intra-articular injection of resveratrol delays cartilage degeneration in C57BL/6 mice by inducing autophagy via AMPK /mTOR pathway
852. Long-term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK /mTOR pathway
853. Resveratrol down-regulates a glutamate-induced tissue plasminogen activator via Erk and AMPK /mTOR pathways in rat primary cortical neurons
854. Epigallocatechin-3-Gallate (EGCG) Promotes Autophagy-Dependent Survival via Influencing the Balance of mTOR –AMPK Pathways upon Endoplasmic Reticulum Stress
855. Shengmai injection attenuates the cerebral ischemia/reperfusion induced autophagy via modulation of the AMPK , mTOR and JNK pathways
856. Role of nutraceutical SIRT1 modulators in AMPK and mTOR pathway: Evidence of a synergistic effect
857. Isoflurane Preconditioning Alleviated Murine Liver Ischemia and Reperfusion Injury by Restoring AMPK /mTOR -Mediated Autophagy
858. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK /mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung cancer Cells
859. SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibit ion ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK /mTOR /SREBP1 pathway and ROS production in HepG2 cells
860. β‐asarone inhibit ed cell growth and promoted autophagy via P53/Bcl‐2/Bclin‐1 and P53/AMPK /mTOR pathways in Human Glioma U251 cells
861. Tris (1, 3-dichloro-2-propyl) phosphate induces apoptosis and autophagy in SH-SY5Y cells: Involvement of ROS-mediated AMPK /mTOR /ULK1 pathways
862. Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK /mTOR signaling pathway
863. Acute stimulation of glucose influx upon mitoenergetic dysfunction requires LKB1, AMPK , Sirt2 and mTOR –RAPTOR
864. SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK )-Mammalian Target of Rapamycin (mTOR ) Signaling, and inhibit s Proliferation of HepG2 Hepatocarcinoma Cells
865. Eugenol Ameliorates Hepatic Steatosis and Fibrosis by Down-Regulating SREBP1 Gene Expression via AMPK –mTOR -p70S6K Signaling Pathway
866. Silencing Nrf2 impairs glioma cell proliferation via AMPK -activated mTOR inhibit ion
867. Suppression of c-Myc induces apoptosis via an AMPK /mTOR -dependent pathway by 4-O-methyl-ascochlorin in leukemia cells
868. Functional Effects of a Pathogenic Mutation in Cereblon (CRBN) on the Regulation of Protein Synthesis via the AMPK –mTOR Cascade
869. Hydrogen peroxide inhibit s mTOR signaling by activation of AMPK α leading to apoptosis of neuronal cells
870. The endotoxemia cardiac dysfunction is attenuated by AMPK /mTOR signaling pathway regulating autophagy
871. Pleurotus nebrodensis polysaccharide(PN50G) evokes A549 cell apoptosis by the ROS/AMPK /Pi3k /AKT/mTOR pathway to suppress tumor growth
872. Akt/AMPK /mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells
873. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5′-AMP-activated protein kinase (AMPK )/mTOR and Pi3k /Akt/mTOR pathways
874. Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK –mTOR -p70S6K signaling pathway
875. Netrin-1 Improves Functional Recovery through Autophagy Regulation by Activating the AMPK /mTOR Signaling Pathway in Rats with Spinal Cord Injury
876. Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK /Akt/mTOR signaling and autophagy
877. Rhein inhibit s Autophagy in Rat Renal Tubular Cells by Regulation of AMPK /mTOR Signaling
878. Cucurbitacin E ameliorates hepatic fibrosis in vivo and in vitro through activation of AMPK and blocking mTOR -dependent signaling pathway
879. Global Liver Proteome Analysis Using iTRAQ Reveals AMPK –mTOR –Autophagy Signaling Is Altered by Intrauterine Growth restriction in Newborn Piglets
880. A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancer s through activation of LKB1-AMPK –mTOR signaling pathway
881. The mTOR /Pi3k and MAPK pathways converge on eIF4B to control its phosphorylation and activity
882. Targeting the Pi3k /Akt/mTOR pathway: Effective combinations and clinical considerations
883. Pi3k /AKT/mTOR pathway in angiogenesis
884. Targeting the Pi3k –AKT–mTOR pathway: progress, pitfalls, and promises
885. Targeting the Pi3k /Akt/mTOR Pathway – Beyond Rapalogs
886. Regulation of Dendritic Morphogenesis by Ras–Pi3k –Akt–mTOR and Ras–MAPK Signaling Pathways
887. Overcoming acquired resistance to anticancer therapy: focus on the Pi3k /AKT/mTOR pathway
888. De novo somatic mutations in components of the Pi3k -AKT3-mTOR pathway cause hemimegalencephaly
889. Contributions of the Raf/MEK/ERK, Pi3k /PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
890. Strategies for co-targeting the Pi3k /AKT/mTOR pathway in NSCLC
891. insulin -like Growth Factor-1 (IGF-1) Inversely Regulates Atrophy-induced Genes via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (Pi3k /Akt/mTOR ) Pathway
892. The role of Pi3k /AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration
893. Restraining Pi3k : mTOR signalling goes back to the membrane
894. Role of the Pi3k /AKT and mTOR signaling pathways in acute myeloid leukemia
895. Involvement of Pi3k /PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9
896. The Pi3k -Akt-mTOR pathway in initiation and progression of thyroid tumors
897. The Pi3k /Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
898. Activation of the Pi3k /mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
899. Pharmacogenomic profiling of the Pi3k /PTEN-AKT-mTOR pathway in common human tumors
900. The TORrid affairs of viruses: effects of mammalian DNA viruses on the Pi3k –Akt–mTOR signalling pathway
901. The RAS/RAF/MEK/ERK and the Pi3k /AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
902. Pi3k /Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibit ors as anticancer agents: Structural and pharmacological perspectives
903. Pi3k /Akt/mTOR signaling pathway and targeted therapy for glioblastoma
904. PDGFRs are critical for Pi3k /Akt activation and negatively regulated by mTOR
905. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
906. Targeting the translational apparatus to improve leukemia therapy: roles of the Pi3k /PTEN/Akt/mTOR pathway
907. Complementary genomic approaches highlight the Pi3k /mTOR pathway as a common vulnerability in osteosarcoma
908. Targeting the Pi3k /Akt/mTOR pathway in hepatocellular carcinoma
909. Transformation by v-Src: Ras-MAPK and Pi3k –mTOR Mediate Parallel Pathways
910. inhibit ion of Pi3k /mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
911. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, Pi3k /PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
912. Pi3k -FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival
913. The Pi3k -Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
914. Aberrant STAT5 and Pi3k /mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
915. Status of Pi3k /Akt/mTOR Pathway inhibit ors in Lymphoma
916. Pi3k /AKT signaling pathway and cancer : an updated review
917. Resveratrol downregulates Pi3k /Akt/mTOR signaling pathways in human U251 glioma cells
918. Activation of the Pi3k -Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy
919. β-Caryophyllene oxide inhibit s growth and induces apoptosis through the suppression of Pi3k /AKT/mTOR /S6K1 pathways and ROS-mediated MAPKs activation
920. Emerging roles of the p38 MAPK and Pi3k /AKT/mTOR pathways in oncogene-induced senescence
921. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR signaling pathways
922. Crosstalk Between the Pi3k /mTOR and MEK/ERK Pathways Involved in the Maintenance of Self‐Renewal and Tumorigenicity of Glioblastoma Stem‐Like Cells
923. Combined targeting of MEK and Pi3k /mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
924. Management of Metabolic Effects Associated With Anticancer Agents Targeting the Pi3k -Akt-mTOR Pathway
925. PI-103 and Sorafenib inhibit Hepatocellular Carcinoma Cell Proliferation by Blocking Ras/Raf/MAPK and Pi3k /AKT/mTOR Pathways
926. Dual targeting of the Pi3k /Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
927. Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the Pi3k /Akt/mTOR Pathway
928. Activation of the N-Ras–Pi3k –Akt-mTOR Pathway by Hepatitis C Virus: Control of Cell Survival and Viral Replication
929. Pi3k /Akt/mTOR pathway inhibit ors in the therapy of pancreatic neuroendocrine tumors
930. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.
931. Targeting the Pi3k /AKT/mTOR pathway in squamous cell carcinoma of the head and neck
932. Leptin regulates proliferation and apoptosis of colorectal carcinoma through Pi3k /Akt/mTOR signalling pathway
933. Preclinical Rationale for Pi3k /Akt/mTOR Pathway inhibit ors as Therapy for Epidermal Growth Factor Receptor inhibit or-Resistant Non–Small-Cell Lung cancer
934. Targeting the Pi3k /AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
935. Synergistic effects between auristatin-based antibody drug conjugates and inhibit ors of the Pi3k -AKT mTOR pathway
936. Activation of the Pi3k /mTOR /AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
937. inhibit ion of the Pi3k /AKT/mTOR Pathway in Solid Tumors
938. Targeting the Pi3k /AKT/mTOR Pathway: Biomarkers of Success and Tribulation
939. Pyrazino[2,3-b]pyrazine mTOR kinase inhibit ors for oncology indications and diseases associated with the mTOR /Pi3k /Akt pathway
940. Advanced glycation endproducts trigger autophagy in cadiomyocyte Via RAGE/Pi3k /AKT/mTOR pathway
941. Roles of Pi3k /AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses
942. Pi3k ing the Lock: Targeting the Pi3k /Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma
943. Suppression of Feedback Loops Mediated by Pi3k /mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
944. Dysregulation of the IGF-I/Pi3k /AKT/mTOR signaling pathway in autism spectrum disorders
945. The Pi3k /Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
946. Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise.
947. Targeting the RTK-Pi3k –mTOR Axis in Malignant Glioma: Overcoming Resistance
948. Evidence for Down-Regulation of Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin (Pi3k /Akt/mTOR )-Dependent Translation Regulatory Signaling Pathways in Ames Dwarf Mice
949. 9-Aminoacridine-based anticancer drugs target the Pi3k /AKT/mTOR , NF-κB and p53 pathways
950. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: Pi3k /Akt/PTEN, mTOR , SHH/PTCH and angiogenesis
951. AKTivation of Pi3k /AKT/mTOR signaling pathway by KSHV
952. Autophagy suppression promotes apoptotic cell death in response to inhibit ion of the Pi3k —mTOR pathway in pancreatic adenocarcinoma
953. IGF‐1‐stimulated protein synthesis in oligodendrocyte progenitors requires Pi3k /mTOR /Akt and MEK/ERK pathways
954. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibit ion of Pi3k /Akt/mTOR pathway
955. Loss of Tsc1/Tsc2 activates mTOR and disrupts Pi3k -Akt signaling through downregulation of PDGFR
956. Activation of RAF/MEK/ERK and Pi3k /AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
957. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo
958. Potential therapeutic targets for chordoma: Pi3k /AKT/TSC1/TSC2/mTOR pathway
959. The Pi3k /AKT/mTOR interactive pathway
960. The critical role of IL-15–Pi3k –mTOR pathway in natural killer cell effector functions
961. Targeting the Pi3k /mTOR pathway in pediatric hematologic malignancies
962. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (Pi3k -Akt-mTOR ) signaling pathway in non-small cell lung cancer
963. Caffeine induces apoptosis by enhancement of autophagy via Pi3k /Akt/mTOR /p70S6K inhibit ion
964. Silica nanoparticles induce autophagy and endothelial dysfunction via the Pi3k /Akt/mTOR signaling pathway
965. Activation of the Pi3k /Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder
966. Increased activation of Pi3k /AKT signaling pathway is associated with cholangiocarcinoma metastasis and Pi3k /mTOR inhibit ion presents a possible therapeutic strategy
967. The Role of Pi3k /Akt/mTOR Signaling in Gastric Carcinoma
968. IL-22 induced cell proliferation is regulated by Pi3k /Akt/mTOR signaling cascade
969. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the Pi3k /Akt/mTOR pathway
970. Therapeutic Priority of the Pi3k /AKT/mTOR Pathway in Small Cell Lung cancer s as Revealed by a Comprehensive Genomic Analysis
971. Targeting the Pi3k /Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential
972. PF-04691502, a Potent and Selective Oral inhibit or of Pi3k and mTOR Kinases with Antitumor Activity
973. SMAD-Pi3k -Akt-mTOR Pathway Mediates BMP-7 Polarization of Monocytes into M2 Macrophages
974. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the Pi3k /Akt/mTOR /GCLc/redox signaling pathway
975. Selective inhibit ion of Pi3k /Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque
976. Increased AKT S473 phosphorylation after mTOR C1 inhibit ion is rictor dependent and does not predict tumor cell response to Pi3k /mTOR inhibit ion
977. HBx induces HepG-2 cells autophagy through Pi3k /Akt–mTOR pathway
978. Targeting Pi3k /AKT/mTOR network for treatment of leukemia
979. Characterization of the Activity of the Pi3k /mTOR inhibit or XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the Pi3k Pathway
980. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
981. Ablation of Pi3k blocks BCR-ABL leukemogenesis in mice, and a dual Pi3k /mTOR inhibit or prevents expansion of human BCR-ABL+ leukemia cells
982. The Pi3k /Akt and mTOR /P70S6K Signaling Pathways in Human Uveal Melanoma Cells: Interaction with B-Raf/ERK
983. Mutations and Deregulation of Ras/Raf/MEK/ERK and Pi3k /PTEN/Akt/mTOR Cascades Which Alter Therapy Response
984. Activation of Pi3k /mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
985. Clinical potential of novel therapeutic targets in breast cancer : CDK4/6, Src, JAK/STAT, PARP, HDAC, and Pi3k /AKT/mTOR pathways
986. Multipoint targeting of the Pi3k /mTOR pathway in mesothelioma
987. Differential Effects of Selective inhibit ors Targeting the Pi3k /AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
988. Vertical inhibit ion of the Pi3k /Akt/mTOR pathway for the treatment of osteoarthritis
989. Downregulation of Pi3k /Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice
990. Intranasally delivered siRNA targeting Pi3k /Akt/mTOR inflammatory pathways protects from aspergillosis
991. Thyroid Hormone Stimulates Protein Synthesis in the Cardiomyocyte by Activating the Akt-mTOR and p70S6K Pathways
992. inhibit ion of Notch Signaling Promotes the Adipogenic Differentiation of Mesenchymal Stem Cells Through Autophagy Activation and PTEN-Pi3k /AKT/mTOR Pathway
993. A Pan-cancer Proteogenomic Atlas of Pi3k /AKT/mTOR Pathway Alterations
994. Pi3k /AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth
995. Identification of a Role for the Pi3k /AKT/mTOR Signaling Pathway in Innate Immune Cells
996. Targeting the Pi3k /AKT/mTOR signaling network in acute myelogenous leukemia
997. Pi3k -Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update
998. Synergistic inhibit ion of ovarian cancer cell growth by combining selective Pi3k /mTOR and RAS/ERK pathway inhibit ors
999. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
1000. Regulation of survivin expression by IGF-1/mTOR signaling